Home About us Editorial board Search Ahead of print Current issue Archives Submit article Instructions Subscribe Contacts Login 
ORIGINAL ARTICLE
Year : 2018  |  Volume : 31  |  Issue : 1  |  Page : 299-305

Evaluation of intraoperative use of mitomycin C in subscleral trabeculectomy surgery


1 Department of Ophthalmology, Lions Eye Hospital, Ashmoun, Egypt
2 Department of Ophthalmology, Faculty of Medicine, Menoufia University, Shebin El-Kom, Menoufia Governorate, Egypt

Correspondence Address:
Mohab M El-Qattan
Ashmoun, Menoufia Governorate, Egypt
Egypt
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/mmj.mmj_84_17

Rights and Permissions

Objective The aim of the study was to evaluate the effectiveness and complications of mitomycin C(MMC) use in subscleral trabeculectomy surgery. Background MMC is an antimetabolite agent used to limit the scarring process, which is the main cause of failure of subscleral trabeculectomy surgery. However, it may increase the incidence of adverse effects. Patients and methods A prospective interventional study involving 35 eyes of 28patients having glaucoma was conducted. All of them underwent subscleral trabeculectomy with adjuvant intraoperative use of MMC(0.2mg/ml) for 2min, and were followed up for at least 9months recording intraocular pressure(IOP) testing, best corrected visual acuity, Seidel testing, bleb grading according to the Indiana bleb appearance grading scale, and complications if present. Results The mean IOP decreased from 32.03mmHg preoperatively to 13.83mmHg at 9months postoperatively. The mean IOP drop registered was 56.82%. Overall, 29(82.9%) eyes ended with complete success, three(8.6%) eyes ended with qualified success, and three(8.6%) eyes failed. The incidence of complications was 51.5%, and most of them were transient and self-limited conditions. Further management, including both medications and minor procedures, improved the postoperative outcomes. Conclusion MMC of 0.2mg/ml used for 2min intraoperatively is an effective adjunctive treatment in patients with glaucoma; however, with this dose, it is associated with some complications. So it is a double-edged weapon that should be used wisely, only when indicated, with optimum concentration and duration.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed443    
    Printed8    
    Emailed0    
    PDF Downloaded34    
    Comments [Add]    

Recommend this journal